Trials / Unknown
UnknownNCT02145013
Portal Hypertension and Liver Resection in Patients With Hepatocellular Carcinoma
Assessment and Impact of Portal Hypertension Before and During Liver Resection in Patients With Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Henri Mondor University Hospital · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
According to the BCLC guidelines, surgical resection of hepatocellular carcinoma complicating cirrhosis is restricted to patients with preserved liver function, single nodule without vascular invasion and with hepatic venous gradient below 10 mmHg. However, other guideline treatment, especially from eastern countries demonstrated that surgical resection is safe and feasible and provides better survival than the treatment recommended by the BCLC system for patients with similar stage. The primary goal of this study is to assess the impact of HVPG on short and long-term outcomes in HCC patients who undergo liver resection.
Detailed description
Patients with HCC and candidates for hepatectomy are classified into two groups according to the presence of portal hypertension. Short- and long-term outcomes will be compared.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Liver resection | Hepatectomy by either open, laparoscopic or robotic procedures |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2017-12-01
- Completion
- 2018-05-30
- First posted
- 2014-05-22
- Last updated
- 2018-02-12
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02145013. Inclusion in this directory is not an endorsement.